To explore the genetic basis of clonal hematopoiesis and its consequences, researchers analyzed genotyping data for more than 151,000 UK Biobank participants.
The Seoul-based company also recently raised $1.9 million in series B funding and is targeting between $7 million and $8 million to close the round.
Amgen will use BC Platforms' tools and services to study data in multiple indications, including cardiovascular and bone diseases, hematological malignancies, and other cancers.
Tempus will work with the center to develop personalized medicine regimens for cancer patients, initially focusing on hematological and pancreatic malignancies.
The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
The firms will develop tests in the hematology oncology space where detecting large structural variations of the genome is crucial for accurate diagnoses.
The Mayo Medical Laboratories laboratory is offering mate-pair sequencing for cancer and inherited disease indications, with plans to expand the service.
The two companies are expanding a long-term collaboration to include development and commercialization of assays for the Applied Biosystems 3500Dx system.
The data included results from thousands of clinically tested samples showing frequent identification of clinically useful diagnostic and prognostic markers.
The Mayo team aims to launch MP-seq for hematological malignancies and constitutional diseases in the next year and for solid tumors one year later.
Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.
Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.
In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.
Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.